BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20013016)

  • 1. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
    Horn DL; Ostrosky-Zeichner L; Morris MI; Ullmann AJ; Wu C; Buell DN; Kovanda LL; Cornely OA
    Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):223-9. PubMed ID: 20013016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF; Lortholary O; Ostrosky-Zeichner L; Stucker F; Yeldandi V
    Crit Care; 2009; 13(5):R159. PubMed ID: 19804626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
    Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
    Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
    Shorr AF; Wu C; Kothari S
    J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ; Hille D; Sable CA; Kartsonis NA
    J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
    Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
    Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Micafungin for the treatment of neonatal invasive candidiasis].
    Infante-López ME; Rojo-Conejo P
    Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.